Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine for ADHD in Adolescents and Young Adults With SUD
NCT01207622Phase 4Withdrawn
- Sponsor
- Massachusetts General Hospital
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of atomoxetine in attention deficit hyperactivity disorder (ADHD), sponsored by Massachusetts General Hospital. Status: withdrawn.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT01207622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01207622.